BN Business News
Add your company to Business Communicator →

Business · 22/10/20261 min read

Rznomics has been awarded the Orphan Medicinal Product Designation for RZ-001 for the Treatment of Glioma by the European Commission.

Summary

SEONGNAM, South Korea, 22 October 2026 — Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced today that the European Commission (EC) has granted...

Original source language: PR Newswire — Global News ReleasesOpen original release →

Explore insights

Business insights →